From: Isolation of T cell receptors specifically reactive with mutated tumor associated antigens
TCR sourcea,b | TCR α/βc | media | T2+ HBVd peptide | T2+ mutated AHNAKe peptide | T2+ wild type AHNAK peptide | T2+ mutated SRPXf peptide | T2+ wild type SRPX peptide | Allogeneic melanoma (A2+) | Autologous melanoma (A2+) |
---|---|---|---|---|---|---|---|---|---|
peptide stimulated PBLa | TRAV12-2*01/ TRBV2*01 | 118 | 167 | >10000 | 698 | 220 | 244 | 85 | 9784 |
peptide stimulated PBL | TRAV19*01/ TRBV12-4*01 | 90 | 100 | 150 | 154 | >10000 | 246 | 60 | 9715 |
peptide stimulated PBL | TRAV3*01/ TRBV2*01 | 84 | 84 | 121 | 105 | >10000 | 217 | 34 | >10000 |
CD137 FACS sorted TILb | TRAV29/DV5*01/ TRBV5-6*01 | 126 | 134 | 139 | 189 | >10000 | 183 | 55 | >10000 |